Hla class I a2 tumor associated antigen peptides and vaccine compositions
OwnerJohn D Fikes, Alessandro Sette +5inventors
InventorsJohn D Fikes, Alessandro Sette, John Sidney, Scott Southwood, Esteban Celis, Elissa A Keogh, Robert Chestnut
Life of this patent
Estimating the term…
Abstract
A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.
Claims39
A composition comprising at least a one peptide, the peptide comprising an isolated, prepared epitope consisting of a sequence selected from the group consisting of:
- 19 VLYGPDAPTV, (SEQ ID NO:1) YLSGANLNV, (SEQ ID NO:2) ATVGIMIGV, (SEQ ID NO:3) LLPENNVLSPV, (SEQ ID NO:4) KLCPVQLWV, (SEQ ID NO:5) KLBPVQLWV, (SEQ ID NO:6) SLPPPGTRV, (SEQ ID NO:7) SMPPPGTRV, (SEQ ID NO:8) KLFGSLAFV, (SEQ ID NO:9) KVFGSLAFV, (SEQ ID NO:10) VMAGVGSPYV, (SEQ ID NO:11) ALCRWGLLL, (SEQ ID NO:12) FLWGPRALV, (SEQ ID NO:13) HLYQGCQVV, (SEQ ID NO:14) ILHNGAYSL, (SEQ ID NO:15) IMIGVLVGV, (SEQ ID NO:16) KIFGSLAFL, (SEQ ID NO:17) KVAELVHFL, (SEQ ID NO:18) LLTFWNPPV, (SEQ ID NO:19) LVFGIELMEV, (SEQ ID NO:20) QLVFGIELMEV, (SEQ ID NO:21) RLLQETELV, (SEQ ID NO:22) VVLGVVFGI, (SEQ ID NO:23) YLQLVFGIEV, and (SEQ ID NO:24) YMIMVKCWMI. (SEQ ID NO:25)
A composition comprising one or more peptides, and further comprising at least two epitopes selected from the group consisting of:
- 20 VLYGPDAPTV, (SEQ ID NO:1) YLSGANLNV, (SEQ ID NO:2) ATVGIMIGV, (SEQ ID NO:3) LLPENNVLSPV, (SEQ ID NO:4) KLCPVQLWV, (SEQ ID NO:5) KLBPVQLWV, (SEQ ID NO:6) SLPPPGTRV, (SEQ ID NO:7) SMPPPGTRV, (SEQ ID NO:8) KLFGSLAFV, (SEQ ID NO:9) KVFGSLAFV, (SEQ ID NO:10) VMAGVGSPYV, (SEQ ID NO:11) ALCRWGLLL, (SEQ ID NO:12) FLWGPRALV, (SEQ ID NO:13) HLYQGCQVV, (SEQ ID NO:14) ILHNGAYSL, (SEQ ID NO:15) IMIGVLVGV, (SEQ ID NO:16) KIFGSLAFL, (SEQ ID NO:17) KVAELVHFL, (SEQ ID NO:18) LLTFWNPPV, (SEQ ID NO:19) LVFGIELMEV, (SEQ ID NO:20) QLVFGIELMEV, (SEQ ID NO:21) RLLQETELV, (SEQ ID NO:22) VVLGVVFGI, (SEQ ID NO:23) YLQLVFGIEV, and (SEQ ID NO:24) YMIMVKCWMI;
- (SEQ ID NO:25)
- wherein each of said one or more peptides comprise less than 50 contiguous amino acids that have 100% identity with a native peptide sequence.
A vaccine composition comprising:
- a unit dose of a peptide that comprises less than 50 contiguous amino acids that have 100% identity with a native peptide sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide comprising an epitope selected from the group consisting of:
- 21 VLYGPDAPTV, (SEQ ID NO:1) YLSGANLNV, (SEQ ID NO:2) ATVGIMIGV, (SEQ ID NO:3) LLPENNVLSPV, (SEQ ID NO:4) KLCPVQLWV, (SEQ ID NO:5) KLBPVQLWV, (SEQ ID NO:6) SLPPPGTRV, (SEQ ID NO:7) SMPPPGTRV, (SEQ ID NO:8) KLFGSLAFV, (SEQ ID NO:9) KVFGSLAFV, (SEQ ID NO:10) VMAGVGSPYV, (SEQ ID NO:11) ALCRWGLLL, (SEQ ID NO:12) FLWGPRALV, (SEQ ID NO:13) HLYQGCQVV, (SEQ ID NO:14) ILHNGAYSL, (SEQ ID NO:15) IMIGVLVGV, (SEQ ID NO:16) KIFGSLAFL, (SEQ ID NO:17) KVAELVHFL, (SEQ ID NO:18) LLTFWNPPV, (SEQ ID NO:19) LVFGIELMEV, (SEQ ID NO:20) QLVFGIELMEV, (SEQ ID NO:21) RLLQETELV, (SEQ ID NO:22) VVLGVVFGI, (SEQ ID NO:23) YLQLVFGIEV, and (SEQ ID NO:24) YMIMVKCWMI;
- and a pharmaceutical (SEQ ID NO:25) excipient.
- a pharmaceutical excipient.
Dependencies are inferred from the claim text.